Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K, Moh R, Chazallon C, Lemoine M, Sylla B, Fadiga F, Le Carrou J, Marcellin F, Kouanfack C, Ciaffi L, Sartre MT, Sida MB, Diallo A, Gozlan J, Seydi M, Cissé V, Danel C, Girard PM, Toni TD, Minga A, Boyer S, Carrieri P, Attia A; TAC ANRS12311 Study Group. Lacombe K, et al. Among authors: chazallon c. Sci Rep. 2024 May 3;14(1):10244. doi: 10.1038/s41598-024-57013-1. Sci Rep. 2024. PMID: 38702350 Free PMC article. Clinical Trial.
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Coelho LE, Chazallon C, Laureillard D, Escada R, N'takpe JB, Timana I, Messou E, Eholie S, Khosa C, Chau GD, Cardoso SW, Veloso VG, Delaugerre C, Molina JM, Grinsztejn B, Marcy O, De Castro N. Coelho LE, et al. Among authors: chazallon c. Open Forum Infect Dis. 2024 Jan 22;11(3):ofae035. doi: 10.1093/ofid/ofae035. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38486816 Free PMC article. Clinical Trial.
Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high tuberculosis burden countries.
De Castro N, Chazallon C, Brites C, Messou E, Khosa C, Laureillard D, Chau GD, Pilotto JH, Eholié S, Delaugerre C, Molina JM, Wittkop L, Grinsztejn B, Marcy O. De Castro N, et al. Among authors: chazallon c. AIDS. 2023 Oct 1;37(12):1837-1842. doi: 10.1097/QAD.0000000000003521. Epub 2023 Feb 16. AIDS. 2023. PMID: 36928120 Clinical Trial.
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis.
De Castro N, Chazallon C, N'takpe JB, Timana I, Escada R, Wagner S, Messou E, Eholie S, Bhatt N, Khosa C, Laureillard D, Do Chau G, Veloso VG, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B, Marcy O; ANRS 12300 Reflate TB2 Study Group. De Castro N, et al. Among authors: chazallon c. Open Forum Infect Dis. 2022 Nov 19;9(12):ofac628. doi: 10.1093/ofid/ofac628. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540390 Free PMC article.
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.
Maitre T, Bonnet M, Calmy A, Raberahona M, Rakotoarivelo RA, Rakotosamimanana N, Ambrosioni J, Miró JM, Debeaudrap P, Muzoora C, Davis A, Meintjes G, Wasserman S, Wilkinson R, Eholié S, Nogbou FE, Calvo-Cortes MC, Chazallon C, Machault V, Anglaret X, Bonnet F. Maitre T, et al. Among authors: chazallon c. Trials. 2022 Nov 8;23(1):928. doi: 10.1186/s13063-022-06772-1. Trials. 2022. PMID: 36348453 Free PMC article.
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N, Marcy O, Chazallon C, Messou E, Eholié S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B; ANRS 12300 Reflate TB2 study group. De Castro N, et al. Among authors: chazallon c. Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2. Lancet Infect Dis. 2021. PMID: 33667406 Clinical Trial.
29 results